We have previously shown that Epstein–Barr virus (EBV)-encoded EBNA-5 is localized to PML bodies (PODs) in EBV-immortalized lymphoblastoid cell lines (LCLs). Here we have extended our study of the subnuclear localization of EBNA-5 and found a strict co-localization with PML in LCLs and in BL lines with an immunoblastic, LCL-like phenotype. Moreover, GFP–EBNA-5 accumulated in PML bodies upon transfection into LCLs. In contrast, transfection of cell lines of non-immunoblastic origin with an EBNA-5 expression construct showed preferential localization of the protein to the nucleoplasm. Since PML is involved in proteasome-dependent protein degradation, we investigated the total levels and sub-cellular localization of EBNA-5 upon inhibition of proteasome activity. We found that a proteasome inhibitor, MG132, induced the translocation of both endogenous and transfected EBNA-5 to the nucleoli in every cell line tested. The total EBNA-5 protein levels were not affected by the proteasomal block. EBNA-5 forms complexes with heat shock protein Hsp70. The proteasome inhibitor induced a rise in total levels of Hsp70 and dramatically changed its homogeneous nuclear and cytoplasmic distribution into nucleolar and cytoplasmic. This effect was EBNA-5-independent. The nucleolar localization of Hsp70 was enhanced by the presence of EBNA-5, however. EBNA-5 also enhanced the nucleolar translocation of a mutant p53 in a colon cancer line, SW480, treated with MG132. The coordinated changes in EBNA-5 and Hsp70 localization and the effect of EBNA-5 on mutant p53 distribution upon MG132 treatment might reflect the involvement of EBNA-5 in the regulation of intracellular protein trafficking associated with the proteasome-mediated degradation.
AbarzuaP.,
LoSardoJ. E.,
GublerM. L.,
NeriA.1995; Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Research 55:3490–3494
AntonL. C.,
SchubertU.,
BacikI.,
PrinciottaM. F.,
WearschP. A.,
GibbsJ.,
DayP. M.,
RealiniC.,
RechsteinerM. C.,
BenninkJ. R.,
YewdellJ. W.1999; Intracellular localization of proteasomal degradation of a viral antigen. Journal of Cell Biology 146:113–124
Ben-BassatH.,
GoldblumN.,
MitraniS.,
GoldblumT.,
YoffeyJ. M.,
CohenM. M.,
BentwichZ.,
RamotB.,
KleinE.,
KleinG.1977; Establishment in continuous culture of a new type of lymphocyte from a ‘Burkitt like’ malignant lymphoma (line D G.-75). International Journal of Cancer 19:27–33
BushK. T.,
GoldbergA. L.,
NigamS. K.1997; Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance. Journal of Biological Chemistry 272:9086–9092
Chelbi-AlixM. K.,
de TheH.1999; Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 18:935–941
FinkeJ.,
RoweM.,
ErnbergI.,
RosenA.,
DillnerJ.,
KleinG.1987; Monoclonal and polyclonal antibodies against Epstein–Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt’s lymphoma and lymphoblastoid cell lines. Journal of Virology 61:3870–3878
FourieA. M.,
HuppT. R.,
LaneD. P.,
SangB. C.,
BarbosaM. S.,
SambrookJ. F.,
GethingM. J.1997; HSP70 binding sites in the tumor suppressor protein p53. Journal of Biological Chemistry 272:19471–19479
HolmvallP.,
SzekelyL.1999; Computer programs that allow fast aquisition, visualization and overlap quantitation of fluorescent 3D microscopic objects by using nearest-neighbor deconvolution algorithm. Applied Immunohistochemistry & Molecular Morphology 7:226–236
IshovA. M.,
SotnikovA. G.,
NegorevD.,
VladimirovaO. V.,
NeffN.,
KamitaniT.,
YehE. T.,
StraussJ. F.III.,
MaulG. G.1999; PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. Journal of Cell Biology 147:221–234
KimD.,
KimS. H.,
LiG. C.1999; Proteasome inhibitors MG132 and lactacystin hyperphosphorylate HSF1 and induce hsp70 and hsp27 expression. Biochemical and Biophysical Research Communications 254:264–268
MannickJ. B.,
TongX.,
HemnesA.,
KieffE.1995; The Epstein–Barr virus nuclear antigen leader protein associates with hsp72/hsc73. Journal of Virology 69:8169–8172
MullerS.,
DejeanA.1999; Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. Journal of Virology 73:5137–5143
Pinhasi-KimhiO.,
MichalovitzD.,
Ben-ZeevA.,
OrenM.1986; Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature 320:182–184
QuignonF.,
De BelsF.,
KokenM.,
FeunteunJ.,
AmeisenJ. C.,
de TheH.1998; PML induces a novel caspase-independent death process. Nature Genetics 20:259–265
RickinsonA. B.,
KieffE.1996; Epstein–Barr virus. In Fields Virology pp 2397–2436 Edited by
FieldsB. N.,
KnipeD. M.,
HowleyP. M.
Philadelphia: Lippincott–Raven;
SinclairA. J.,
PalmeroI.,
PetersG.,
FarrellP. J.1994; EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalisation of resting human B lymphocytes by Epstein–Barr virus. EMBO Journal 13:3321–3328
SzekelyL.,
SelivanovaG.,
MagnussonK.,
KleinG.,
WimanK. G.1993; EBNA-5, an Epstein–Barr virus encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proceedings of the National Academy of Sciences, USA 90:5455–5459
SzekelyL.,
JiangW.-Q.,
PokrovskajaK.,
WimanK. G.,
KleinG.,
RingertzN.1995a; Reversible nucleolar translocation of Epstein–Barr virus-encoded EBNA-5 and hsp70 proteins after exposure to heat shock or cell density congestion. Journal of General Virology 76:2423–2432
ZhengP.,
GuoY.,
NiuQ.,
LevyD. E.,
DyckJ. A.,
LuS.,
SheimanL. A.,
LiuY.1998; Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 396:373–376